160 related articles for article (PubMed ID: 35778653)
21. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Le Cesne A; Blay JY; Cupissol D; Italiano A; Delcambre C; Penel N; Isambert N; Chevreau C; Bompas E; Bertucci F; Chaigneau L; Piperno-Neumann S; Salas S; Rios M; Guillemet C; Bay JO; Ray-Coquard I; Haddag L; Bonastre J; Kapso R; Fraslin A; Bouvet N; Mir O; Foulon S
Ann Oncol; 2021 Aug; 32(8):1034-1044. PubMed ID: 33932507
[TBL] [Abstract][Full Text] [Related]
24. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
Nassif EF; Blay JY; Massard C; Dufresne A; Brahmi M; Cassier P; Ray-Coquard I; Pautier P; Leary A; Sunyach MP; Bahleda R; Levy A; Le Pechoux C; Honoré C; Mir O; Le Cesne A
ESMO Open; 2022 Apr; 7(2):100425. PubMed ID: 35255445
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Garcia del Muro X; Lopez-Pousa A; Martin J; Buesa JM; Martinez-Trufero J; Casado A; Poveda A; Cruz J; Bover I; Maurel J;
Cancer; 2005 Oct; 104(8):1706-12. PubMed ID: 16134177
[TBL] [Abstract][Full Text] [Related]
26. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
27. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
Akshintala S; Mallory NC; Lu Y; Ballman KV; Schuetze SM; Chugh R; Maki RG; Reinke DK; Widemann BC; Kim A
Oncologist; 2023 May; 28(5):453-459. PubMed ID: 36724001
[TBL] [Abstract][Full Text] [Related]
31. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.
Peinemann F; Enk H; Smith LA
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD008216. PubMed ID: 28407197
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
34. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
[TBL] [Abstract][Full Text] [Related]
35. Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
Liu X; Jiang S; Wang H; Wu X; Yan W; Chen Y; Xu Y; Wang C; Yao W; Wang J; Yu L; Miao J; Chen H; Xia J; Huang M; Zhang X; Luo Z
Clin Cancer Res; 2022 Dec; 28(24):5280-5289. PubMed ID: 36239473
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
[TBL] [Abstract][Full Text] [Related]
37. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
[TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
40. Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival.
Penel N; Cousin S; Duhamel A; Kramar A
Crit Rev Oncol Hematol; 2013 Nov; 88(2):309-17. PubMed ID: 23706377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
